Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which results in tumor...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Iron regulatory protein 1-deficient mice exhibit hypospermatogenesis.

The Journal of biological chemistry·2024
Same author

Iron regulatory protein 1 is required for the propagation of inflammation in inflammatory bowel disease.

The Journal of biological chemistry·2024
Same author

Soluble CD72, is a T-cell activator probably via binding to CD6 in homeostasis and autoimmunity.

Frontiers in immunology·2024
Same author

Iron regulatory proteins 1 and 2 have opposing roles in regulating inflammation in bacterial orchitis.

JCI insight·2024
Same author

A newly identified ferritin L-subunit variant results in increased proteasomal subunit degradation, impaired complex assembly, and severe hypoferritinemia.

American journal of hematology·2023
Same author

Plexins as Regulators of Cancer Cell Proliferation, Migration, and Invasivity.

Cancers·2023

Related Experiment Video

Updated: Jun 26, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Semaphorins in cancer.

Gera Neufeld1, Niva Shraga-Heled, Tali Lange

  • 1Cancer and Vascular Biology Research Center, Rappaport Research Institute in the Medical Sciences, The Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel. gera@techunix.technion.ac.il

Frontiers in Bioscience : a Journal and Virtual Library
|December 1, 2004
PubMed
Summary

Semaphorins are proteins involved in cell development and migration. Some semaphorins inhibit tumor growth by blocking blood vessel formation, while others may promote it.

More Related Videos

Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker
07:47

Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker

Published on: September 15, 2023

Mammosphere Assay Reveals Api5-Induced Stemness in Non-Tumorigenic Breast Epithelial Cell Lines
08:05

Mammosphere Assay Reveals Api5-Induced Stemness in Non-Tumorigenic Breast Epithelial Cell Lines

Published on: February 24, 2026

Related Experiment Videos

Last Updated: Jun 26, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker
07:47

Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker

Published on: September 15, 2023

Mammosphere Assay Reveals Api5-Induced Stemness in Non-Tumorigenic Breast Epithelial Cell Lines
08:05

Mammosphere Assay Reveals Api5-Induced Stemness in Non-Tumorigenic Breast Epithelial Cell Lines

Published on: February 24, 2026

Area of Science:

  • Molecular Biology
  • Developmental Biology
  • Cancer Biology

Background:

  • Semaphorins are a large gene family with diverse roles in development, including axon guidance and cell migration.
  • Vertebrate semaphorins (classes 3-7) interact with plexin and neuropilin receptors.
  • Class-3 semaphorins, like semaphorin-3B and semaphorin-3F, are implicated in tumor suppression.

Purpose of the Study:

  • To review the roles of semaphorins, their receptors, and signaling pathways.
  • To explore the dual role of semaphorins in tumorigenesis and tumor progression.

Main Methods:

  • Literature review of semaphorin function and signaling.
  • Analysis of evidence linking semaphorins to cancer development.

Main Results:

  • Certain semaphorins (e.g., semaphorin-3A, semaphorin-3F) inhibit tumor growth and angiogenesis.
  • Other semaphorins (e.g., semaphorin-3C, semaphorin-4D) may promote tumorigenesis or progression.
  • Semaphorins modulate cancer cell adhesion and migration.

Conclusions:

  • Semaphorins exhibit context-dependent roles in cancer, acting as both tumor suppressors and promoters.
  • Understanding semaphorin signaling is crucial for developing novel cancer therapies.